GSK 299423
Подписчиков: 0, рейтинг: 0
|
| |
|
| |
| Names | |
|---|---|
|
Preferred IUPAC name
6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile | |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChemSpider |
|
|
PubChem CID
|
|
| UNII | |
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C25H27N5O2S | |
| Molar mass | 461.58 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs.
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.
No animal studies have been reported. No application has been made for human clinical trials.
| Medical microbiology |
|||||||
|---|---|---|---|---|---|---|---|
|
Biochemistry and ecology |
|
||||||
| Shape | |||||||
| Structure |
|
||||||
|
Taxonomy and evolution |
|||||||